From Central Office

Vox Sanguinis highlights

Fresh from the press

Original article

Transfusion efficacy of leucoreduced packed red blood cells prepared by two different methods: A randomized controlled trial in transfusion-dependent thalassaemia patients (FUEL trial)

Open access

Click here

Adhikarimayum Arunkumari, Ashish Jain, Sheetal Malhotra, Hari Krishan Dhawan, Srinivasan Peyam, Sangeeta Kumari, Ratti Ram Sharma

Article Highlights:

  • The mean haemoglobin (Hb) content of leucoreduced packed red blood cells prepared using the standard method (SLPRBCs) was 50.60 ± 5.12 g, while that of PRBCs prepared using a new method whereby leucoreduction of whole blood is carried out first (NLPRBCs) was 56.98 ± 5.92 g.
  • Over the 3-month study period, the mean transfusion interval was 20.30 ± 3.75 days for Group I patients, who were transfused with SLPRBCs, while it was 21.34 ± 5.13 days for Group II patients, who were transfused with NLPRBCs.
  • A significant positive correlation was observed between the Hb dose transfused and the Hb increment with both SLPRBC and NLPRBC transfusions.

First published: 16 January 2025


Original article

Notification of blood donors who test positive for transfusion-transmissible infections

Open access

Click here

Sheila F. O'Brien, Kiyuri Naicker, Lori Osmond, Kelly Holloway, Steven J. Drews, Mark Bigham, Mindy Goldman

Article Highlights:

  • Donors are notified of confirmed positive tests by registered letter, and provincial/territorial public health departments are notified as required by law. The majority of donors who participated in the study were successfully notified that they had a confirmed positive transmissible disease test result.
  • Most donors were surprised to learn that they had a confirmed positive transmissible disease test, suggesting that most donors were not aware of their infection before the notification of donor testing results.
  • Not all donors with confirmed positive donation testing results chose to see a physician about their results.tate stored at 1–6°C for 7 days meets quality specifications for coagulation factor (F) VIII (≥70 IU/unit), von Willebrand factor (>100 IU/unit) and fibrinogen (≥140 mg/unit).

First published: 14 January 2025


Short report

Engaging with young professionals in transfusion medicine: Insights from a needs assessment survey targeting an international cohort

Open access

Click here

Eunike C. McGowan, Antoine Lewin, Jian Ou-Yang (Nikita), Saikat Mandal, Nour Almozain, Abiy Belay Ambaye, Jannison Karlly Cavalcante Ribeiro, Lilian Antwi Boateng, Carla Luana Dinardo, Praiseldy Langi Sasongko, on behalf of the Young Professionals Council

Article Highlights:

  • This survey aimed to assess the needs of young professionals globally, which included International Society of Blood Transfusion (ISBT) members and non-members from all World Health Organization regions.
  • Findings showed that the primary reason for a lack of engagement in ISBT activities was a lack of awareness from both members and non-members.
  • Engagement can be improved by raising awareness of ISBT activities, along with customizing transfusion-related educational content.

First published: 12 January 2025


Review

Investigating the impact of mitochondrial DNA: Insights into blood transfusion reactions and mitigation strategies

Open access

Click here

Saeede Bagheri, Fatemeh Hajiabadi, Reihaneh Vahabzadeh, Mohammad Hossein Ahmadi

Article Highlights:

  • Mitochondrial DNA (mtDNA) is a damage-associated molecular pattern (DAMP) present in blood products.
  • mtDNA could trigger adverse transfusion reactions, such as febrile non-haemolytic transfusion reactions, acute respiratory distress syndrome, transfusion-related acute lung injury and non-haemolytic transfusion reactions.
  • Optimizing preparation techniques, donor selection criteria and utilizing fresh blood components could minimize mtDNA release into blood products.

First published: 8 January 2025

Contents